All In Biotech

Investigational drug · Phase 3

NX-5948

Also called: bexobrutideg

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

7

Any phase or sponsor naming "NX-5948"

First trial start

2025

Oct 15, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NX-5948", any sponsor or status.

Conditions studied

As listed on its trial records.

  • B-cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers

Largest trials

Live from ClinicalTrials.gov: studies naming "NX-5948" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for B-cell Lymphoma

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • TQB3702Phase 22 trials

    Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · B-cell Lymphoma, Systemic Lupus Erythematosus

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.